Revelation Biosciences, Inc.

Name: Revelation Biosciences, Inc. standardized financial statements, quarterly
Creator: Listed

REVBNasdaqCIK 1810560HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.7m, Q2 FY2026

Net income−$3.3m, Q2 FY2026

Revelation Biosciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$k	1,651	1,060	718	1,395	831	606	859	1,318	923	964	1,377	1,918
Operating income	$k	(2,778)	(2,326)	(1,902)	(2,522)	(1,797)	(1,754)	(2,095)	(2,461)	(1,943)	(2,572)	(3,093)	(3,662)
Income tax	$k	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported
Net income	$k	(2,628)	(2,203)	(2,681)	(8,390)	(2,242)	(1,726)	(2,051)	(2,444)	(1,907)	(2,511)	(3,009)	(3,323)
Diluted EPS	$ per share	(9.94)	not reported	(39.37)	(246.27)	(40.15)	not reported	(25.34)	(28.04)	(1.77)	not reported	(2.71)	(0.87)
Basic EPS	$ per share	(9.94)	not reported	(39.37)	(246.27)	(40.15)	not reported	(25.34)	(28.04)	(1.77)	not reported	(2.71)	(0.87)

Balance sheet

Cash and equivalents$11.5m, Q2 FY2026

Shareholders' equity$10.1m, Q2 FY2026

Revelation Biosciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	14.0	12.0	14.6	12.1	6.5	6.5	3.7	5.2	12.7	10.7	14.1	11.5
Current assets	$m	14.1	12.1	14.6	12.2	6.7	6.6	3.9	5.4	12.8	10.8	14.2	11.7
Total assets	$m	14.2	12.2	14.7	12.3	6.7	6.6	4.0	5.4	12.9	11.6	15.0	12.5
Current liabilities	$m	5.4	5.6	5.2	11.1	4.1	1.9	1.1	1.6	1.9	2.0	1.4	1.9
Total liabilities	$m	5.4	5.6	5.2	11.1	4.1	1.9	1.1	1.6	1.9	2.7	2.1	2.4
Shareholders' equity	$m	8.8	6.6	9.5	1.1	2.7	4.7	2.9	3.8	11.0	8.9	13.0	10.1

Cash flow

Operating cash flow−$2.6m, Q2 FY2026

Capital expenditure$39.6k, Q2 FY2026

Revelation Biosciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,717)	(2,003)	(2,838)	(2,479)	(9,257)	(3,748)	(2,794)	(1,919)	(1,589)	(1,967)	(3,215)	(2,557)
Capital expenditure	$k	0.0	not reported	19.2	0.0	17.7	(17.7)	not reported	not reported	not reported	not reported	71.9	39.6

Diluted shares (weighted)3.83m, Q2 FY2026

Revelation Biosciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	612	166	248	265	68.1	34.1	55.8	80.9	201	2,645	3,208	3,829

Shares outstanding: 3.98m at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.